Sulfanilamide

Sulfanilamide

SCHEMBL1955933

NS(=O)(=O)c1ccc(NCC2CCOCC2)cc1.Nc1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfanilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 16/20 0.47
CA1 P00915 15/20 0.47
CA9 Q16790 15/20 0.47
HTT P42858 1/20 0.47
CA12 O43570 11/20 0.46
CA4 P22748 4/20 0.46
CA14 Q9ULX7 4/20 0.46
CA6 P23280 3/20 0.46
CA5A P35218 3/20 0.46
CA7 P43166 3/20 0.46
CA5B Q9Y2D0 3/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AGO2 Q9UKV8 1/20 0.46
CNR2 P34972 1/20 0.45
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
RORC P51449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2482925 0.94 CNR2 (0.48) CA2CA1CA9CA12CA4
SCHEMBL1238818 0.81 CA2 (0.58) CA2CA1CA9CA12CA4
SCHEMBL15718561 0.80 PTGS2 (0.55) TSHRCNR2ALDH1A1
SCHEMBL28184974 0.80 CA2 (0.50) CA2CA1CA9CA12CA4
SCHEMBL28299165 0.78 CA2 (0.50) CA2CA1CA9CA12TDP1
SCHEMBL1700398 0.77 BRD4 (0.48) CA2CA1CA9CA12CNR2
SCHEMBL16054069 0.77 GBA1 (0.55) CA2CA1CA9CA12CA4
SCHEMBL1700346 0.76 CA2 (0.51) CA2CA1CA9CA12CA5A
SCHEMBL10187375 0.75 PTGER4 (0.42) HTTALDH1A1
SCHEMBL2935193 0.75 PTGER4 (0.42) HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507229-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 EP disclosed
EP-2507211-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 EP disclosed
EP-2376480-A2 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP disclosed
WO-2011068561-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed
WO-2011068560-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 WO disclosed